GlycoTherapeutics

Executive Summary

GlycoTherapeutics is a Netherlands-based drug development startup focused on overcoming the efficacy limitations of current cancer immunotherapies. Less than 50% of cancer patients receiving immunotherapy achieve a durable response, partly due to glycobiology processes that suppress the immune system. Leveraging over a decade of research, the company's proprietary platform disrupts interactions between glycans (sugars) and immune cells responsible for immune evasion. This approach aims to enhance the effectiveness of existing immunotherapies and expand their benefit to a broader patient population. Currently in Phase 2 development, GlycoTherapeutics is advancing its lead candidate through clinical trials, targeting both solid tumors and hematologic malignancies. With a strong scientific foundation and growing interest in glyco-immunology, the company is positioned to address a critical unmet need in oncology. The team in Leiden is building strategic partnerships to accelerate development and prepare for late-stage clinical trials and potential regulatory filing.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 interim data readout50% success
• TBDStrategic partnership with large pharma30% success
• TBDSeries A/B financing round40% success